Impact of Pembrolizumab Versus Chemotherapy as Second-Line Therapy for Advanced Esophageal Cancer on Health-Related Quality of Life in KEYNOTE-181.

Antoine Adenis,Amit S. Kulkarni,Gustavo Girotto,Christelle De La Fouchardiere,Hélène Senellart,Hanneke W. M. van Laarhoven,Wasat Mansoor,Raed Al-Rajabi,Josephine M. Norquist,Mayur Amonkar,Shailaja Suryawanshi,Pooja Bhagia,Jean-Philippe Metges

Impact of Pembrolizumab Versus Chemotherapy as Second-Line Therapy for Advanced Esophageal Cancer on Health-Related Quality of Life in KEYNOTE-181.

2021

Antoine Adenis
Amit S. Kulkarni
Gustavo Girotto
Christelle De La Fouchardiere
Hélène Senellart
Hanneke W. M. van Laarhoven
Wasat Mansoor
Raed Al-Rajabi
Josephine M. Norquist
Mayur Amonkar
Shailaja Suryawanshi
Pooja Bhagia
Jean-Philippe Metges

PURPOSEIn the phase III KEYNOTE-181 study (NCT02564263) of patients with advanced esophageal cancer (EC), pembrolizumab monotherapy prolonged overall survival versus chemotherapy as second-line the...

Keywords:

overall survival
Oncology
Medicine
health related quality of life
Pembrolizumab
Second-line therapy
Chemotherapy
advanced esophageal cancer
Internal medicine

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations